Last week I wrote about a pending lawsuit by the FDA against Regenerative Sciences,a medical company thatdevelopeda stem cell treatment for orthopedic injuries. Whileadult stem cell therapies have been fraught with concerns about safetyand efficacy, this case is particularly important not only because it is unprecedented the FDA is attempting toclassify non-embryonicstem cellsas drugs but also because itbrings into focusthe disconnect between the pace of scientific progressand the struggle ofregulatorsto keep up withrapidly evolving technologies.
I spoke withthree people with aunique perspective onwhats at stake a lawyer who specializes in FDA regulation, a lab director of an in-vitro fertilization clinic, and a bioethicist to geta sense of how thecase is viewed intheir industries. One common threadthat emergedfrom these conversations is that the FDA is conflicted, even confused,about how to regulate stem cell-based products.Theprolonged legal battle with Regenerative(it dates back to at least 2008) is duelargely to the fact that the agency recognizes the absurdity of coming down with a one-size-fits-all regulatory approach thatwould apply to every clinicoffering such treatments.
To be sure, stem cell medicine has a terrible reputation.Stem cell therapies thatpurport to treateverything fromshot knees and slipped disks toautism, multiple sclerosis,and Parkinsons diseaseare rightlyregarded by many as modern-day quackery. That is because unscrupulous doctors have seized on the promise of this exciting new science and used it to peddle unproventreatments to desperateand ill-informedpatients.
In 2010, CBS aired a 60 Minutes special titled 21st Century Snake Oil,in whichDoug Sipp, a researcher at the RIKEN Center for Developmental Biology in Japan and a critic of stem cell fraud,who also runs the watchdog blog Stem Cell Treatment Monitor, warned of the dangers of blossoming stem cell medical tourism. That same year, NPR aired a story called Offshore Stem Cell Clinics Sell Hope, Not Science.Andin 2011, the journal Naturereported on Texas governor Rick Perrys crusadetosoften the FDAsposition on stem cellclinics,whose number in the U.S.is estimated to be around a dozen.The International Societyfor Stem Cell Research (ISSCR), a non-profit organization of medical doctors and scholars,alsofunctions as amyth busterfor clinically untestedtreatments. On its website, the group writes that themesenchymal stem cell, which is at the heart of the FDA lawsuit andis used byRegenerative in its procedures,has become a cell of intense interestbut has not yet been shown to have a clear-cut advantage over existing therapies, is not considered a standard of care for any condition and does not have regulatory approval for the routine treatment of any disease.
Against this background, the FDA is grappling with a difficult decision how to curb the proliferation of unproven stem cell treatmentshawked by unconscientious doctors, while recognizingthatthis branch ofmedicine holds alegitimatepromise whose full potential is only beginning to be discovered.
Areta Kupchyk, a partner at the law firm Nixon Peabody who counsels clients on FDA regulation and development of new biotechnologies, including human tissue and stem cells, says cell-basedproductsare tough to regulate because they are individualized and manipulated to different degrees for usesin individual patients.
The FDA has been trying to figure out how to regulate stem cell product development because it is so difficult individual hospitals, individual doctors are performing individual procedures. It has hada very difficult time over the years trying to regulate something thats not a big manufacturing facility. Its very hard to get your arms around something like that as a regulatory agency, Kupchyk told me ina telephone interview.
Shenoted that where minimal manipulation is concerned, the FDA may face a special challenge. One of the arguments in the agencys case for regulating Regenexx, a procedure in which adult stem cells are extracted, cultured in a special serum, and reinjected back into the same patient, is thatthe cells are more thanminimally manipulated.
I can understand why the FDA is focusing on minimal manipulation that is something they have been focusing on for a number of years. But they havent been able to articulate what minimal manipulation means. Theyre regulating on a case-by-case basis and theyre not informing the public well on where they draw the line,Kupchyk said.One good reason theyre not coming down is that this area is rapidly evolving and there are products created out of cells that have never been used or created before. So theyre struggling with new products, they are not sure how they are going to work in the body. This case could be very important in forcing the FDA to define it more clearly.
The number ofscientists and clinicsdeveloping or providing adultstem cell treatmentsis another reason the FDA may beat a disadvantage trying toestablish hard-and-fast new rules, Kupchyk added. If the FDA is successful in this case, its going to raise a lot of questions for everyone out there whos trying to develop new uses for stem cells for patients. There may be a chilling effect, certainly, and its very expensive to test new products [through the formal regulatory framework]. If every single physician or clinic who was doing something similar applied, the FDA would not be able to handle it. Thats another reason theyre not coming down on every single case.
View original post here:
Stem Cells, FDA, and the Edge of Science: Three Expert ...
- ACT - Stem Cell Trial for AMD and Stargardt - Phase 1 - September 15th, 2011 [September 15th, 2011]
- Excerpt from: "The Urban Wire" Internet Radio Podcast: FDA Oks embryonic stem cell trials for humans - September 15th, 2011 [September 15th, 2011]
- Advanced Cell Technology (ACT) AMD stem cell clinical phase - September 15th, 2011 [September 15th, 2011]
- Stem Cells Retina and cornea regeneration ACT Dr lanza - Advanced Cell Technology - September 15th, 2011 [September 15th, 2011]
- Spinal Patient Receives Stem Cells in First Experimental Treatment - September 15th, 2011 [September 15th, 2011]
- Bloomberg: Geron, StemCells Rise 4% - September 15th, 2011 [September 15th, 2011]
- Bringing Stem Cell Cures to the Clinic: UC Davis GMP Facility - September 15th, 2011 [September 15th, 2011]
- Researchers in California Show Results for Spinal Cord Injuries Using Embryonic Stem Cells - September 15th, 2011 [September 15th, 2011]
- Bill Caldwell, Chairman - September 20th, 2011 [September 20th, 2011]
- Advanced Cell Technology OneMedForum 2011 - September 20th, 2011 [September 20th, 2011]
- ACT edmund vision stem cells program Advanced Cell Technology - September 20th, 2011 [September 20th, 2011]
- Texans for Stem Cell Research Learn for Life: KXAN Coverage Aired August 16th, 2011 - September 20th, 2011 [September 20th, 2011]
- ACT - Dr Lanza - Hermangioblast program - Advanced cell technology - September 23rd, 2011 [September 23rd, 2011]
- Anticipating the Next Decade of the Genome - Francis Collins, Director of NIH - September 24th, 2011 [September 24th, 2011]
- New Epilepsy Treatment Under Study For Seizures - Part 1 - September 24th, 2011 [September 24th, 2011]
- A Thank You For Trevor Raborn - September 24th, 2011 [September 24th, 2011]
- CBLI Breaking News - September 24th, 2011 [September 24th, 2011]
- What is Cord Blood Banking? The Medical Potential of Newborn Stem Cells - September 24th, 2011 [September 24th, 2011]
- Stem cell medical breakthrough? - September 24th, 2011 [September 24th, 2011]
- NIST Colloquium Series: Next Generation Neural Implants - September 24th, 2011 [September 24th, 2011]
- Alan Lewis: Embryonic Stem Cell Therapies for diabetes - September 24th, 2011 [September 24th, 2011]
- 2011 Predictions for Hair Transplant Developments | Arocha Hair Restoration - September 24th, 2011 [September 24th, 2011]
- Healthbeat - Stem Cell Research - September 24th, 2011 [September 24th, 2011]
- Living With ALS - September 24th, 2011 [September 24th, 2011]
- A Revolutionary New Potential Treatment for Glioblastoma... - September 24th, 2011 [September 24th, 2011]
- Lyme Disease: Challenges and Innovations - September 24th, 2011 [September 24th, 2011]
- 2010: Cord blood saving lives [CNN: 5-30-2011] - September 24th, 2011 [September 24th, 2011]
- Biotechnology, Diagnostics, and Genomics: Panel Discussion - September 24th, 2011 [September 24th, 2011]
- Pharmacogenomics - September 24th, 2011 [September 24th, 2011]
- Brickheads - Osteobots Practice Skit.mpg - September 24th, 2011 [September 24th, 2011]
- A veteran lives with ALS - September 26th, 2011 [September 26th, 2011]
- Healthy Body = Functional Body. Hollywood Look Side Effect: Healthy Function - September 26th, 2011 [September 26th, 2011]
- 2009 Flu Summit: Opening Remarks - September 26th, 2011 [September 26th, 2011]
- Cord Blood Breakthrough - September 28th, 2011 [September 28th, 2011]
- SENS5 - Leucocyte transfusions as a novel immunotherapy for cancer patients - October 2nd, 2011 [October 2nd, 2011]
- Lymphoma Drug SGN-35 - The Nebraska Medical Center - October 2nd, 2011 [October 2nd, 2011]
- ACell Hair Restoration with Dr. Gary Hitzig and Dr. Amiya Prasad - Video - October 14th, 2011 [October 14th, 2011]
- Hans Keirstead: Developing therapies based on embryonic stem cells - Video - October 14th, 2011 [October 14th, 2011]
- NJN News Healthwatch Report - Cornea Treatment Study - Video - October 20th, 2011 [October 20th, 2011]
- HIV/AIDS may be prevented by new lubricant - Video - October 22nd, 2011 [October 22nd, 2011]
- MFIII Switzerland PE Sheep Placenta Glandular therapy Study - Client Interviews - Video - October 22nd, 2011 [October 22nd, 2011]
- Love Diabetes: BCG and Noncompliant Patients - Video - October 25th, 2011 [October 25th, 2011]
- Dr. Alimorad Farshchian statement on embryonic stem cells - Video - October 27th, 2011 [October 27th, 2011]
- StemCellTV Daily Report-October 29, 2011 - Video - October 30th, 2011 [October 30th, 2011]
- Stephen McKenna MD - 8 - Video - October 31st, 2011 [October 31st, 2011]
- ALS Stem Cell Trial at Emory - Video - November 22nd, 2011 [November 22nd, 2011]
- Target Product Profile: Ellen Feigal - 2011 CIRM Grantee Meeting - Video - December 6th, 2011 [December 6th, 2011]
- Monoclonal Antibodies: Stanford Academia-Industry Collaboration - Video - December 8th, 2011 [December 8th, 2011]
- Parkinson's Disease Guidelines (Part 2) - Video - December 9th, 2011 [December 9th, 2011]
- Macular Degeneration Drugs - Video - December 13th, 2011 [December 13th, 2011]
- BrainStorm Cell Therapeutics (OTCBB:BCLI) Has Potentially Developed A Treatment For ALS - January 31st, 2012 [January 31st, 2012]
- StemCells, Inc. Receives FDA Authorization for Age-Related Macular Degeneration Clinical Trial - February 3rd, 2012 [February 3rd, 2012]
- Stemedica Cell Technologies - Documentary - Video - February 4th, 2012 [February 4th, 2012]
- (GMCR, STEM, DSCO) CRWENewswire.com Stocks In Action - Video - February 7th, 2012 [February 7th, 2012]
- Bioheart Acquires Exclusive Rights to Ageless Regenerative Institute's Adipose Cell Technology - February 14th, 2012 [February 14th, 2012]
- Neuralstem Announces Closing of $5.2-Million Registered Direct Offering - February 14th, 2012 [February 14th, 2012]
- Scientists Repair Heart Attack Damage Using Patient's Own Stem Cells To Regrow Healthy Heart Muscle - February 14th, 2012 [February 14th, 2012]
- Stem Cells Regrow Healthy Heart Muscle In Heart Attack Patients - February 15th, 2012 [February 15th, 2012]
- Groundbreaking Clinical Trials Study Cord Blood Stem Cells to Help Treat Brain Injury and Hearing Loss - February 17th, 2012 [February 17th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Lung Cancer Trial With I-124-CLR1404 (Light) Cancer ... - February 22nd, 2012 [February 22nd, 2012]
- IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella ... - February 22nd, 2012 [February 22nd, 2012]
- The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients - February 27th, 2012 [February 27th, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress and New Initiatives - March 1st, 2012 [March 1st, 2012]
- Bioheart Issues Shareholder Letter Announcing Progress - March 1st, 2012 [March 1st, 2012]
- Novelos Therapeutics and Academic Collaborators Have Three Abstracts Accepted for Presentation at 2012 AACR Annual ... - March 1st, 2012 [March 1st, 2012]
- Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344 - March 6th, 2012 [March 6th, 2012]
- Will StemCells Walk The Talk? - March 7th, 2012 [March 7th, 2012]
- Internationally Recognized Leukemia Physician and Researcher to Lead Sylvester Comprehensive Cancer Center - March 7th, 2012 [March 7th, 2012]
- Criminal investigation after patient dies at office of doctor linked to stem cell - March 9th, 2012 [March 9th, 2012]
- Novelos Therapeutics Announces Enrollment of First Patient in Brain Cancer Trial with I-124-CLR1404 (LIGHT) Cancer ... - March 15th, 2012 [March 15th, 2012]
- Vitro Biopharma Receives Approval for Presentation to the International Society for Cellular Therapy - March 20th, 2012 [March 20th, 2012]
- Looking for Innovative Small-Cap Biotech Companies: George Zavoico - March 26th, 2012 [March 26th, 2012]
- Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of ... - March 27th, 2012 [March 27th, 2012]
- Gentium Reports Fourth Quarter and Year End 2011 Financial Results - March 28th, 2012 [March 28th, 2012]
- Basketball’s influence on stem cell treatments in sports medicine - March 30th, 2012 [March 30th, 2012]
- Cardium Announces U.S. Market Introduction of Excellagen™ - March 31st, 2012 [March 31st, 2012]
- Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult ... - March 31st, 2012 [March 31st, 2012]
- New Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who are at High Risk of Clostridium Difficile ... - April 1st, 2012 [April 1st, 2012]
- SynGen Inc. Receives $5 million Equity Investment from Bay City Capital, LLC - April 19th, 2012 [April 19th, 2012]
- Gene Ray, Founder of $2.6 Billion Titan Corp, Invests in Medistem's ERC Technology and Joins Advisory Board - April 26th, 2012 [April 26th, 2012]